<DOC>
	<DOC>NCT02038946</DOC>
	<brief_summary>The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating agent.</brief_summary>
	<brief_title>Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Grade 1, 2, or 3a FL without pathologic evidence of transformation Male and female, ages 18 and above, with relapsed or refractory FL lymphoma after &gt; or =2 prior treatment lines; each of the 2 prior treatment lines must include at least CD20 antibody and/or an alkylating agent Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 01 Known central nervous system lymphoma History of interstitial lung disease Subjects with active, known or suspected autoimmune disease Prior allogeneic stem cell transplant Prior autologous stem cell transplant â‰¤12 weeks prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>